Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 8

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 8
---
 the right directors to continue driving superior stockholder value.

With the re-electionof the two directors your Board has nominated, Dr. Dixon and Ms. Favorito, your Board would continue to be comprised of eight highly-qualified directors, seven of whom are independent and all of whom bring important perspectives and expertise to oversee the continued execution of Zevra’s strategy. We Actively Engaged with Mangless to Try to Avoid a Costly, Potentially Distracting Proxy Contest – Yet He is Intent on Replacing Two Highly-Qualified Directors Over the past several months, we have actively engaged with Mr. Mangless in an attempt to avoid a costly proxy contest that could distract from our continued strong execution. Despite his 2.8% ownership of the Company and having already had three of his nominees elected to the Board in 2023, Mr. Mangless appears intent on trying to secure two additional seats on the Board without providing any specific strategy or plan to meaningfully improve Zevra’s business.Mr. Mangless only expresses dissatisfaction with the Company’s governance structure, without disclosing any expertise or experience regarding the corporate governance practices that are typical for companies of similar size, stage, and/or therapeutic focus to Zevra. Mr. Mangless’ proxy states that he previously shared suggestions about “increasing the diversity of the Board,” but has not described how either of the candidates he has nominated would promote diversity or otherwise align with his own suggestion. As a company dedicated to developing breakthrough therapies for rare diseases, we operate in a highly specialized and complex environment. Success for stockholders, employees, and the patients we help requires an experienced Board with an appropriate mix of perspectives, including deep scientific and commercial expertise, regulatory acumen, financial experience, and the ability to oversee a long-term vision. Despite the significant and recent Board refreshment at Zevra, Mr. Mangless is actively trying to replace two highly-qualified directors who bring valuable industry, operational, and financial expertise to the Board, both of whom have substantial experience in leadership roles and as public company directors:

| Wendy L. Dixon, Ph.D., has served as a director since April 2023 and is a member of the Company’s Audit Committee. Dr. Dixon has more than 40 years of biopharmaceutical industry experience in drug development, with                               
 leadership roles in regulatory affairs and commercial capabilities. Dr. Dixon has held a number of leadership roles at leading publicly-traded companies, including serving as Chief Marketing Officer and President of Global Marketing at          
 Bristol-